13F reference period
Q2 2026
Security Snapshot
Erasca, Inc. - Common Stock, $0.0001 par value per share (ERAS) Institutional Ownership
CUSIP: 29479A108
13F Institutional Holders and Ownership History from Q3 2021 to Q3 2026
Institutions Reporting
256
Shares (Excl. Options)
280.36M
Full value: 280,355,932 · shares · 30 Jun 2026Price
$18.32
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- ERAS on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 280,355,932
- Total 13F value
- $5,127,410,877
- Portfolio coverage rank
- 0.01%
- Share change
- +8,120,363
- Value change
- +$176,921,750
- Number of holders
- 256
- Shares outstanding
- 355,466,212
- SEC-reported price per share
- $15.46
- Insider filing price
- $15.46
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ERAS - Erasca, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 29479A108.
- 256 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 223 to 256 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$4.38B
Full value: $4,380,561,876 · USD · 31 Mar 2026.$5.13B
Full value: $5,127,410,877 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 256 institutions filings for Q2 2026.
Security key
29479A108
13F reference period
Q2 2026
13F holders
256
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
ERAS full holder history
Erasca, Inc. SEC filings
Erasca, Inc. company facts
Erasca, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29479A108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
ERAS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| City Hill, LLC | 10% | $697,595,331 | 36,968,486 | Jonathan E. Lim | 30 Jun 2026 | |||
| T. Rowe Price Investment Management, Inc. | 6.8% | +18% | $368,453,223 | +$88,759,076 | 21,224,264 | +32% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 5.3% | $284,405,616 | 16,382,812 | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 | |||
| RTW INVESTMENTS, LP | 5.2% | $280,488,558 | 16,157,175 | RTW Investments, LP | 31 Mar 2026 | |||
| Frazier Life Sciences Public Fund, L.P. | 5.3% | -34% | $21,355,029 | -$10,702,679 | 15,038,753 | -33% | Frazier Life Sciences Public Fund, L.P. | 30 Jun 2025 |
| Logos Global Management LP | 4.8% | -10% | $29,648,000 | -$3,270,000 | 13,600,000 | -9.9% | Logos Global Management LP | 30 Sep 2025 |
| NOVARTIS PHARMA AG | 4.4% | $17,107,692 | 12,307,692 | Novartis Pharma AG | 31 Dec 2024 | |||
| Paradigm Biocapital Advisors LP | 3.3% | -40% | $180,417,307 | -$82,744,582 | 10,392,702 | -31% | Paradigm BioCapital Advisors LP | 31 Mar 2026 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1.1% | -80% | $59,631,027 | -$192,123,762 | 3,434,967 | -76% | Suvretta Capital Management, LLC | 31 Mar 2026 |
As of 30 Jun 2026,
256
institutional investors reported holding
shares of
Erasca, Inc. - Common Stock, $0.0001 par value per share (ERAS).
This represents
79%
of the company’s total
outstanding shares.
280.36M
Full value: 280,355,932 · shares · 30 Jun 2026355.47M
Full value: 355,466,212 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
63%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7% | 24,975,188 | +1.2% | 10% | $457,545,444 |
| T. Rowe Price Investment Management, Inc. | 6% | 21,185,839 | -0.35% | 0.25% | $388,125,000 |
| BlackRock, Inc. | 6% | 21,154,146 | +5% | 0.01% | $387,543,955 |
| RTW INVESTMENTS, LP | 5% | 17,946,754 | +11% | 2.8% | $328,784,533 |
| Venrock Adviser, LLC | 5% | 17,891,812 | +9.2% | 9.9% | $327,777,996 |
| STATE STREET CORP | 3.4% | 12,184,555 | +31% | 0.01% | $223,221,048 |
| Logos Global Management LP | 3.4% | 12,150,000 | +9% | 9.6% | $222,588,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 11,402,199 | +1.4% | 0% | $208,888,286 |
| Siren, L.L.C. | 3.2% | 11,397,781 | +1.4% | 4.2% | $208,807,348 |
| Paradigm Biocapital Advisors LP | 2.7% | 9,550,000 | -8.1% | 3.3% | $174,956,000 |
| ARCH Venture Management, LLC | 2% | 7,091,557 | 0% | 12% | $129,917,324 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 6,501,426 | +8.4% | 0.01% | $119,128,739 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 6,272,508 | +246% | 0.01% | $114,914,000 |
| Cormorant Asset Management, LP | 1.7% | 6,000,000 | +3.4% | 5.7% | $109,920,000 |
| Affinity Asset Advisors, LLC | 1.5% | 5,250,000 | -1.9% | 4.7% | $96,180,000 |
| Vivo Capital, LLC | 1.2% | 4,127,412 | -66% | 6.9% | $75,614,188 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 4,118,614 | 0% | 0.02% | $66,639,175 |
| GOLDMAN SACHS GROUP INC | 1.1% | 3,822,113 | -22% | 0.01% | $70,021,110 |
| BANK OF AMERICA CORP /DE/ | 0.86% | 3,048,737 | -0.23% | 0% | $55,852,862 |
| FMR LLC | 0.81% | 2,883,417 | +94% | 0% | $52,824,202 |
| a16z Capital Management, L.L.C. | 0.81% | 2,862,500 | 0% | 0.37% | $52,441,000 |
| Woodline Partners LP | 0.8% | 2,831,867 | +0.01% | 0.16% | $51,879,803 |
| JENNISON ASSOCIATES LLC | 0.78% | 2,788,412 | 0.03% | $51,083,708 | |
| Soleus Capital Management, L.P. | 0.76% | 2,700,000 | 1.7% | $49,464,000 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.67% | 2,389,864 | +35% | 0% | $43,782,308 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
21
Headline period
Q2 2026
Rows shown
1-21 of 21
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 8,391,297 | $122,861,680 | +$58,546,236 | $14.66 | 50 |
| 2026 Q2 | 280,355,932 | $5,127,410,877 | +$176,921,750 | $18.32 | 256 |
| 2026 Q1 | 270,827,927 | $4,380,561,876 | +$843,119,076 | $16.18 | 223 |
| 2025 Q4 | 219,275,999 | $815,702,675 | +$5,117,573 | $3.72 | 153 |
| 2025 Q3 | 214,909,404 | $468,512,239 | -$3,508,720 | $2.18 | 138 |
| 2025 Q2 | 218,177,770 | $277,145,224 | -$8,196,772 | $1.27 | 141 |
| 2025 Q1 | 224,275,876 | $307,274,963 | -$9,730,312 | $1.37 | 151 |
| 2024 Q4 | 230,866,824 | $579,481,287 | -$3,886,798 | $2.51 | 144 |
| 2024 Q3 | 232,039,374 | $633,439,326 | +$46,910,487 | $2.73 | 130 |
| 2024 Q2 | 203,567,396 | $480,459,612 | +$311,839,926 | $2.36 | 124 |
| 2024 Q1 | 72,681,232 | $149,721,765 | +$6,866,672 | $2.06 | 105 |
| 2023 Q4 | 69,247,665 | $147,523,921 | -$3,989,593 | $2.13 | 115 |
| 2023 Q3 | 71,279,487 | $140,403,646 | -$6,391,863 | $1.97 | 106 |
| 2023 Q2 | 74,333,071 | $205,158,369 | -$10,901,012 | $2.76 | 110 |
| 2023 Q1 | 78,047,305 | $234,907,735 | -$11,497,274 | $3.01 | 115 |
| 2022 Q4 | 79,824,946 | $344,037,900 | +$2,800,974 | $4.31 | 106 |
| 2022 Q3 | 80,523,466 | $628,084,382 | +$33,781,376 | $7.80 | 87 |
| 2022 Q2 | 76,887,302 | $428,260,749 | +$21,982,237 | $5.57 | 87 |
| 2022 Q1 | 72,825,959 | $626,627,487 | +$45,427,981 | $8.60 | 80 |
| 2021 Q4 | 63,677,801 | $987,988,866 | +$64,674,674 | $15.58 | 63 |
| 2021 Q3 | 44,137,190 | $918,521,616 | +$918,521,616 | $21.22 | 53 |